Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hubert Chen

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
The Journal of Allergy and Clinical Immunology|April 1, 2014
Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumabAidan Long, Abdelkader Rahmaoui, Kenneth J Rothman, et al.
Applied Optics|May 10, 2003
W/SiC x-ray multilayers optimized for use above 100 keVDavid L Windt, Soizik Donguy, Charles J Hailey, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 10, 2015
Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background TherapyThomas B Casale, Jonathan A Bernstein, Marcus Maurer, et al.
Therapeutic Advances in Respiratory Disease|November 29, 2025
Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjectsPaul Miller, Daniel Repplinger, Rui Zhu, et al.
The Journal of Allergy and Clinical Immunology|September 19, 2016
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthmaCarlos Iribarren, Abdelkader Rahmaoui, Aidan A Long, et al.
Environmental Health : a Global Access Science Source|May 22, 2010
An integrated model of environmental factors in adult asthma lung function and disease severity: a cross-sectional studyLaura Trupin, John R Balmes, Hubert Chen, et al.
Chest|March 12, 2011
Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL RegistryLynette M Brown, Hubert Chen, Scott Halpern, et al.
American Journal of Clinical Dermatology|April 12, 2025
Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis BullosaM Peter Marinkovich, Amy S Paller, Shireen V Guide, et al.
American Journal of Clinical Dermatology|June 4, 2025
Correction to: Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis BullosaM Peter Marinkovich, Amy S Paller, Shireen V Guide, et al.
American Journal of Respiratory and Critical Care Medicine|September 12, 2022
The Lung Allocation Score Remains Inequitable for Patients with Pulmonary Arterial Hypertension, Even after the 2015 RevisionNicholas A Kolaitis, Hubert Chen, Daniel R Calabrese, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
The Journal of Allergy and Clinical Immunology|April 1, 2014
Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumabAidan Long, Abdelkader Rahmaoui, Kenneth J Rothman, et al.
Applied Optics|May 10, 2003
W/SiC x-ray multilayers optimized for use above 100 keVDavid L Windt, Soizik Donguy, Charles J Hailey, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 10, 2015
Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background TherapyThomas B Casale, Jonathan A Bernstein, Marcus Maurer, et al.
Therapeutic Advances in Respiratory Disease|November 29, 2025
Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjectsPaul Miller, Daniel Repplinger, Rui Zhu, et al.
The Journal of Allergy and Clinical Immunology|September 19, 2016
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthmaCarlos Iribarren, Abdelkader Rahmaoui, Aidan A Long, et al.
Environmental Health : a Global Access Science Source|May 22, 2010
An integrated model of environmental factors in adult asthma lung function and disease severity: a cross-sectional studyLaura Trupin, John R Balmes, Hubert Chen, et al.
Chest|March 12, 2011
Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL RegistryLynette M Brown, Hubert Chen, Scott Halpern, et al.
American Journal of Clinical Dermatology|April 12, 2025
Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis BullosaM Peter Marinkovich, Amy S Paller, Shireen V Guide, et al.
American Journal of Clinical Dermatology|June 4, 2025
Correction to: Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis BullosaM Peter Marinkovich, Amy S Paller, Shireen V Guide, et al.
American Journal of Respiratory and Critical Care Medicine|September 12, 2022
The Lung Allocation Score Remains Inequitable for Patients with Pulmonary Arterial Hypertension, Even after the 2015 RevisionNicholas A Kolaitis, Hubert Chen, Daniel R Calabrese, et al.
Pageof 6